SCHEMBL3868626

SCHEMBL3868626

COc1ccc(COC(=O)Br)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.57
HTT P42858 2/20 0.55
NPC1 O15118 1/20 0.53
POLB P06746 1/20 0.53
RAB9A P51151 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
IDO1 P14902 2/20 0.52
AGXT P21549 2/20 0.52
MMP9 P14780 2/20 0.51
MMP1 P03956 1/20 0.51
KMT2A Q03164 1/20 0.51
LDHA P00338 1/20 0.50
FFAR1 O14842 1/20 0.50
MMP2 P08253 1/20 0.50
MMP12 P39900 1/20 0.50
ATM Q13315 1/20 0.49
FABP7 O15540 1/20 0.49
FABP5 Q01469 1/20 0.49
P2RX4 Q99571 1/20 0.49
MAPT P10636 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL155140 0.85 ALDH1A1 (0.57) ALDH1A1HTTNPC1POLBRAB9A
SCHEMBL292834 0.84 ALDH1A1 (0.60) ALDH1A1HTTNPC1POLBRAB9A
SCHEMBL3758807 0.84 ALDH1A1 (0.60) ALDH1A1HTTNPC1POLBRAB9A
SCHEMBL292835 0.82 NPC1 (0.59) ALDH1A1HTTNPC1POLBRAB9A
SCHEMBL1871228 0.82 ALDH1A1 (0.62) ALDH1A1HTTNPC1POLBRAB9A
SCHEMBL112518 0.82 ALDH1A1 (0.62) ALDH1A1HTTNPC1POLBRAB9A
SCHEMBL6403295 0.82 ALDH1A1 (0.58) ALDH1A1HTTNPC1POLBRAB9A
Bromoethane SCHEMBL9571773 0.82 ALDH1A1 (0.51) ALDH1A1HTTNPC1POLBRAB9A
SCHEMBL14303017 0.81 PARP10 (0.53) ALDH1A1NPC1POLBRAB9ASMN1; SMN2
SCHEMBL2679069 0.81 ALDH1A1 (0.56) ALDH1A1HTTNPC1POLBRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090149444-A1 Benzylamine analogues BTG INTERNATIONAL LIMITED (GB) 2009-06-11 US disclosed
US-7514475-B2 Benzylamine analogues BTG INTERNATIONAL LIMITED (GB) 2009-04-07 US disclosed
US-7504437-B2 Benzylamine analogues BTG INTERNATIONAL LIMITED (GB) 2009-03-17 US disclosed
US-7504393-B2 Benzylamine analogues BTG INTERNATIONAL LIMITED (GB) 2009-03-17 US disclosed
US-20080255095-A1 Benzylamine analogues BTG INTERNATIONAL LIMITED (GB) 2008-10-16 US disclosed
EP-1362844-B1 BENZYLAMINE ANALOGUE BTG INT LTD (GB) 2007-12-05 EP disclosed
US-20070037795-A1 2-methyl-1-[2-(4-nitrophenoxy)-ethyl]-1,2,3,4-tetrahydroisoquinolin-6-yl dimethylcarbamate; Acetylcholinesterase inhibitors; selective serotonin reuptake inhibitory; Alzheimer's disease, depression, Huntington's chorea, Pick's disease, tardive dyskinesia, compulsive disorders or panic disorders BTG INTERNATIONAL LIMITED (GB) 2007-02-15 US disclosed
US-20070037793-A1 2-methyl-1-[2-(4-nitrophenoxy)-ethyl]-1,2,3,4-tetrahydroisoquinolin-6-yl dimethylcarbamate; Acetylcholinesterase inhibitors; selective serotonin reuptake inhibitory; Alzheimer's disease, depression, Huntington's chorea, Pick's disease, tardive dyskinesia, compulsive disorders or panic disorders BTG INTERNATIONAL LIMITED (GB) 2007-02-15 US disclosed
US-20040067981-A1 Acetylcholinesterase inhibitor; Alzheimer's diseases, Hubtington disease, antidepressants SANKYO COMPANY, LIMITED (JP) 2004-04-08 US disclosed
EP-1362844-A1 BENZYLAMINE ANALOGUE Sankyo Company, Limited (JP) 2003-11-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070037793-A1 2-methyl-1-[2-(4-nitrophenoxy)-ethyl]-1,2,3,4-tetrahydroisoquinolin-6-yl dimethylcarbamate; Acetylcholinesterase inhibitors; selective serotonin reuptake inhibitory; Alzheimer's disease, depression, Huntington's chorea, Pick's disease, tardive dyskinesia, compulsive disorders or panic disorders CHRNA4, SLC6A4, DRD4 ALDH1A1 1070/4885HTT 44/4885NPC1 459/4885
US-20070037795-A1 2-methyl-1-[2-(4-nitrophenoxy)-ethyl]-1,2,3,4-tetrahydroisoquinolin-6-yl dimethylcarbamate; Acetylcholinesterase inhibitors; selective serotonin reuptake inhibitory; Alzheimer's disease, depression, Huntington's chorea, Pick's disease, tardive dyskinesia, compulsive disorders or panic disorders SLC6A4, SLC6A3, HTR4 ALDH1A1 1017/4885HTT 15/4885NPC1 302/4885
US-20040067981-A1 Acetylcholinesterase inhibitor; Alzheimer's diseases, Hubtington disease, antidepressants ACHE, BACE1, CHRNA6 ALDH1A1 166/4885HTT 19/4885NPC1 410/4885
US-20090149444-A1 Benzylamine analogues HTR4, DRD4, SLC6A4 ALDH1A1 910/4885HTT 21/4885NPC1 623/4885
US-20080255095-A1 Benzylamine analogues NR4A3, NAT1, HRH4 ALDH1A1 1247/4885HTT 1340/4885NPC1 2941/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.